BioCatalystWatch
NXTCWorkspace / NXTC / OverviewCompany library
Price
Market cap
Next catalystExpected 2027AVR-001 · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

NC181

ApoE4

PreINDP1P2P3FilingApproved
NC605

Siglec-15

PreINDP1P2P3FilingApproved
AVR-001

Peptide

IL-23 receptor

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

NC605

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AVR-001

Peptide

IL-23 receptor

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

NC181

ApoE4

PreINDP1P2P3FilingApproved
NC605

Siglec-15

PreINDP1P2P3FilingApproved

Other pipelines

AVR-001

Peptide

IL-23 receptor

AVR-001

Peptide

IL-23 receptor

AVR-001

Peptide

IL-23 receptor

Partner / License out

B7-H4

PreINDP1P2P3FilingApproved

B7-H4

PreINDP1P2P3FilingApproved

B7-H4

PreINDP1P2P3FilingApproved

B7-H4

PreINDP1P2P3FilingApproved

History / paused

Tumor collagen

PreINDP1P2P3FilingApproved

Tumor collagen

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

NXTC PR & News

NXTC SEC archive